Clinical management of plasma cell leukemia: an update Francesca Gay, MD, PhD, of the University of Turin, Turin, Italy, briefly describes the major differences in the clinical presentation of plasma cell leukemia (PCL) and multiple myeloma (MM), including age, severity and risk of chromosomal abnormalities, despite both being plasma cell neoplasms. Dr Gay goes on […]
Read More
Adding checkpoint inhibitor to chemotherapy improves responses without negatively impacting … Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients’ ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women’s Cancer Center investigators shows. The report, coupled with […]
Read More
Metastatic Cancer Treatment Market Size To Be Worth USD 111.16 Billion by 2027 | Emergen … Vancouver, British Columbia, Dec. 10, 2020 (GLOBE NEWSWIRE) — The Global Metastatic Cancer Treatment Market is projected to be worth USD 111.16 Billion by 2027, according to the current analysis by Emergen Research. The market is anticipated to witness […]
Read More
Harvard study details link between obesity and cancer; finds condition accelerates tumour growth Harvard study details link between obesity and cancer; finds condition accelerates tumour growth& |  Photo Credit: iStock Images Key Highlights Obesity is a major risk factor for various diseases and conditions Obesity has also been found to increase risk of contraction and complications […]
Read More Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG … SHANGHAI and HONG KONG, Dec. 10, 2020 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National […]
Read More